Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03550794 · ClinicalTrials.gov registry record · Phase 2
Thiamine as a Renal Protective Agent in Septic Shock
A Phase 2 study of Sepsis and Kidney Injury, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 4
- Study locations
NCT03550794 is a Phase 2 study of Sepsis and Kidney Injury that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 95 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT03550794, a Phase 2 study of Sepsis and Kidney Injury, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin B1) on renal function in septic shock.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Thiamine Hydrochloride
Study Locations (4)
New York
- Northshore University Hospital - Manhasset
- Montefiore Medical Center - New York
- Long Island Jewish Hospital - Queens
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2018-09-04 |
| Est. Completion | 2022-04-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03550794
The ClinicalTrials.gov registry entry for NCT03550794 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03550794 reports 4 study locations spanning 2 distinct geographic areas - top geographies include New York, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03550794 about?
NCT03550794 is a clinical study titled "Thiamine as a Renal Protective Agent in Septic Shock". This is a randomized, double-blind, placebo controlled study to investigate the effect of intravenous thiamine (vitamin B1) on renal function in septic shock.
What is the current status of trial NCT03550794?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2018-09-04. Estimated completion is 2022-04-05.
What conditions does trial NCT03550794 study?
This clinical trial studies the following conditions: Sepsis, Kidney Injury, Thiamine Deficiency.
What interventions are being tested in trial NCT03550794?
The interventions under investigation include: Placebo (DRUG), Thiamine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03550794?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03550794 being conducted?
This trial has 4 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
RECRUITING · Phase 2
-
An Acupuncture Study for People At High Risk for Sepsis
RECRUITING · Phase 2
-
Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection
COMPLETED · Phase 2
-
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.